Imeglimin is a novel agent currently in development to treat type 2 diabetes and has also been shown to normalize glucose tolerance and improve insulin sensitivity by protecting mitochondrial function from oxidative stress [22]. Here, INS is linked to type 2 diabetes mellitus.